Publications 2011

Amarteifio E., Weber M.A., Wormsbecher S., Demirel S., Krakowski-Roosen H., Jöres A., Braun S., Delorme S., Böckler D., Kauczor H.U., Krix M.: Dynamic contrast-enhanced ultrasound for assessment of skeletal muscle microcirculation in peripheral arterial disease. Invest.Radiol. 46 (8) 504-508, 2011.

Arab K., Smith L.T., Gast A., Weichenhan D., Huang J., Claus R., Hielscher T., Espinosa A.V., Ringel M.D., Morrison C.D., Schadendorf D., Kumar R., Plass C.: Epigenetic deregulation of TCF21 inhibits metastasis suppressor KISS1 in metastatic melanoma. Carcinogen. 32 (10) 1467-1473, 2011.

Becker N., Tödt G., Lichter P., Benner A.: Elastic SCAD as a novel penalization method for SVM classification tasks in high-dimensional data. BMC Bioinformatics 12 (1) 138, 2011.

Cin H., Meyer C., Herr R., Janzarik W.G., Lambert S., Jones D.T., Jacob K., Benner A., Witt H., Remke M., Bender S., Falkenstein F., Van Anh T.M., Olbrich H., von Deimling A., Pekrun A., Kulozik A.E., Gnekow A., Scheurlen W., Witt O., Omran H., Jabado N., Collins V.P., Brummer T., Marschalek R., Lichter P., Korshunov A., Pfister S.M.: Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol. 121 (6) 763-774, 2011.

Edler L.: as member of the EFSA Panel on Contaminants in the Food Chain (CONTAM): Scientific opinion on Tetrabromobisphenol A (TBBPA) and its derivatives in food. EFSA J. 9 (12) 2477(61p.), 2011.

Edler L.: as member of the EFSA Panel on Contaminants in the Food Chain (CONTAM): Scientific opinion on the risk to public health related to the presence of high levels of dioxins and dioxin-like PCBs in liver from sheep and deer. EFSA J. 9 (7) 2297(71p.), 2011.

Edler L.: as member of the EFSA Panel on Contaminants in the Food Chain (CONTAM): Scientific opinion on hexabromocyclododecanes (HBCDDs) in food. EFSA J. 9 (7) 2296(118p.), 2011.

Edler L.: as member of the EFSA Panel on Contaminants in the Food Chain (CONTAM): Scientific opinion on the risks for public health related to the presence of zearalenone in food. EFSA J. 9 (6) 2197(124p.), 2011.

Edler L.: as member of the EFSA Panel on Biological Hazards (BIOHAZ) and EFSA Panel on Contaminants in the Food Chain (CONTAM): Scientific opinion on a summary of scientific studies undertaken by the UK Food Standards Agency to support a proposed production method for smoked "skin-on" sheep meat. EFSA J. 9 (6) 2191(38p.), Parma, Italy, 2011.

Edler L.: as member of the EFSA Panel on Contaminants in the Food Chain (CONTAM): Scientific opinion on polybrominated diphenyl ethers (PBDEs) in food. EFSA J. 9 (5) 2156(274p.), 2011.

Edler L.: as member of the EFSA Scientific Committee: Statistical significance and biological relevance (scientific opinion). EFSA J. 9 (9) 2372(17p.), 2011.

Edler L.: as member of the EFSA Panel on Contaminants in the Food Chain (CONTAM): Scientific opinion - Statement on oral toxicity of endosulfan in fish. EFSA J. 9 (4) 2131(22p.), 2011.

Edler L.: as member of the EFSA Panel on Contaminants in the Food Chain (CONTAM): Scientific opinion on the evaluation of the substances currently on the list in the annex to Commission Directive 96/3/EC as acceptable previous cargoes for edible fats and oils - Part I of III. EFSA J. 9 (12) 2482-(61p.), 2011.

Edler L.: as member of the EFSA Panel on Contaminants in the Food Chain (CONTAM): Scientific opinion on pyrrolizidine alkaloids in food and feed. EFSA J. 9 (11) 2406(134p.), 2011.

Edler L.: as member of the EFSA Panel on Contaminants in the Food Chain (CONTAM): Scientific opinion on the risks animal and public health related to the presence of alternaria toxins in feed and food. EFSA J. 9 (10) 2407(97pp.), 2011.

Edler L.: as member of the EFSA Panel on Contaminants in the Food Chain (CONTAM): Scientific opinion on the risks for public health related to the presence of opium alkaloids in poppy seeds. EFSA J. 9 (11) 2405(150p.), 2011.

Edler L.: as member of the EFSA Panel on Contaminants in the Food Chain (CONTAM): Scientific opinion - Statement on tolerable weekly intake for cadmium. EFSA J. 9 (2) 1975(19p.), 2011.

Edler L.: as member of the EFSA Panel on Contaminants in the Food Chain (CONTAM): Scientific opinion on the risks for animal and public health related to the presence of T-2 and HT-2 toxin in food and feed. EFSA J. 9 (12) 2481(187p.), 2011.

Fussbroich B., Wagener N., Macher-Göppinger S., Benner A., Fälth M., Sültmann H., Holzer A., Hoppe-Seyler K., Hopp-Seyler F.: EZH2 depletion blocks the proliferation of colon cancer cells. PLoS_ONE 6 (7) e21651(14p.), 2011.

Georges R.B., Adwan H., Hamdi H., Hielscher T., Linnemann U., Berger M.R.: The insulin-like growth factor binding proteins 3 and 7 are associated with colorectal cancer and liver metastasis. Cancer Biol.Therap. 12 (1) 69-79, 2011.

Halama N., Michael S., Kloor M., Zörnig I., Benner A., Spille A., Pommerencke T., Knebel-Doeberitz D.M.v., Folprecht G., Luber B., Feyen N., Martens U.M., Beckhove P., Gnjatic S., Schirmacher P., Herpel E., Weitz J., Grabe N., Jäger D.: Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res. 71 (17) 5670-5677, 2011.

Heckmann D., Laufs S., Maier P., Zucknick M., Giordano F.A., Veldwijk M.R., Eckstein V., Wenz F., Zeller W.J., Frühauf S., Allgayer H.: A Lentiviral CXCR4 overexpression and knockdown model in colorectal cancer cell lines reveals plerixafor-dependent suppression of SDF-1a-induced migration and invasion. Onkol. 34 (10) 502-508, 2011.

Henrich K.O., Bauer T., Schulte J., Ehemann V., Deubzer H.E., Gogolin S., Muth D., Fischer M., Benner A., König R., Schwab M., Westermann F.: CAMTA1, a 1p36 tumor suppressor candidate, inhibits growth and activates differentiation programs in neuroblastoma cells. Cancer Res. 71 (8) 3142-3151, 2011.

Hillengass J., Stieltjes B., Bäuerle T., McClanathan F., Heiss C., Hielscher T., Wagner-Gund B., Habetier V., Goldschmidt H., Schlemmer H.P., Delorme S., Zechmann C.M.: Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted imaging of bone marrow in healthy individuals. Acta Radiol. 52 (3) 324-330, 2011.

Hillengass J., Bäuerle T., Bartl R., Andrulis M., McClanathan F., Laun F.B., Zechmann C.M., Shah R., Wagner-Gund B., Simon D., Heiss C., Neben K., Ho A.D., Schlemmer H.P., Goldschmidt H., Delorme S., Stieltjes B.: Diffusion-weighted imaging for non-invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histology. Br.J.Haematol. 153 (6) 721-728, 2011.

Hose D., Reme T., Hielscher T., Moreaux J., Messner T., Seckinger A., Benner A., Shaughnessy J.D., Barlogie B., Zhou Y., Hillengass J., Bertsch U., Neben K., Möhler T., Rossi J.F., Jauch A., Klein B., Goldschmidt H.: Proliferation is a central independent prognostic factor and target for personalized and risk adapted treatment in multiple myeloma. Haematologica 96 (1) 87-95, 2011.

Kahlert C., Lahes S., Radhakrishnan P., Dutta S., Mogler C., Herpel E., Brand K., Steinert G., Schneider M., Mollenhauer M., Reissfelder C., Klupp F., Fritzmann J., Wunder C., Benner A., Kloor M., Huth C., Contin P., Ulrich A., Koch M., Weitz J.: Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro. Clin.Cancer Res. 17, 7654-7663, 2011.

Kaufmann M., Pusztai L., Cardoso F., Dietel M., Edler L., Hahn M., Jonat W., Karn T., Kreipe H., Loi S., Minckwitz G.v., Rody A., Sinn H.P., Van de Vijver M.: Use of standard markers and incorporation of molecular markers into breast cancer therapy. Consensus recommendations from an international expert panel. Cancer 117, 1575-1582, 2011.

Kayser S., Döhner K., Krauter J., Köhne C.H., Horst H.A., Held G., Lilienfeld-Toal M.v., Wilhelm S., Kündgen A., Götze K., Rummel M., Nachbaur D., Schlegelberger B., Göhring G., Späth D., Morlok C., Zucknick M., Ganser A., Döhner H., Schlenk R.F.: The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 117 (7) 2137-2145, 2011.

Klein U., Jauch A., Hielscher T., Hillengass J., Raab M.S., Seckinger A., Hose D., Ho A.D., Goldschmidt H., Neben K.: Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone. Cancer 117 (10) 2136-2144, 2011.

Klein U., Neben K., Hielscher T., Heiss C., Ho A.D., Goldschmidt H.: Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. Ann.Hematol. 90 (4) 429-439, 2011.

Knöfel L.F., Werle-Schneider G., Dally H., Müller P.J., Edler L., Bartsch H., Tüngerthal S., Heussel C.P., Thomas M., Risch A.: Polymorphisms in the apoptotic-pathway gene BCL-2 and survival in small cell lung cancer. J.Thoracic Oncol. 6 (1) 183-189, 2011.

Krauter J., Wagner K., Stadler M., Dammann E., Zucknick M., Eder M., Buchholz S., Mischak-Weissinger E., Hertenstein B., Ganser A.: Prognostic factors in allo-SCT of elderly patients with AML. Bone Marrow Transplant. 46, 545-551, 2011.

Kvinlaug B.T., Chan W.I., Bullinger L., Ramaswami M., Sears C., Foster D., Lazic S.E., Okabe R., Benner A., Lee B.H., De Silva I., Valk P.J., Delwel R., Armstrong S.A., Döhner H., Gilliland D.G., Huntly B.J.: Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias. Cancer Res. 71 (12) 4117-4129, 2011.

Kwiecien R., Kopp-Schneider A., Blettner M.: Konkordanzanalyse: Teil 16 der Serie zur Bewertung wissenschaftlicher Publikationen (Concordance Analysis-Part 16 of a Series on Evaluation of Scientific Publications). Dtsch.Ärztebl. 108 (30) 515-521, 2011.

Ley-Zaporozhan J., Molinari F., Risse F., Puderbach M., Schenk J.P., Kopp-Schneider A., Kauczor H.U., Ley S.: Repeatability and reproducibility of quantitative whole-lung perfusion magnetic resonance imaging. J.Thorac.Imag. 26 (3) 230-239, 2011.

Luft T., Dietrich S., Falk C., Conzelmann M., Hess M., Benner A., Neumann F., Isermann B., Hegenbart U., Ho A.D., Dreger P.: Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood 118 (6) 1685-1692, 2011.

Meißner T., Seckinger A., Reme T., Hielscher T., Möhler T., Neben K., Goldschmidt H., Klein B., Hose D.: Gene expression profiling in multiple myeloma--Reporting of entities, risk, and targets in clinical routine. Clin.Cancer Res. 17 (23) 7240-7247, 2011.

Milde T., Kleber S., Korshunov A., Witt H., Hielscher T., Kopp H.G., Jugold M., Deubzer H.E., Öhme I., Lodrini M., Gröne H.J., Benner A., Brüstle O., Gilberston R.J., Deimling A.v., Kulozik A.E., Pfister S.M., Martin-Villalba A., Witt O.: A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat. Acta Neuropathol. 122 (5) 637-650, 2011.

Northcott P.A., Hielscher T., Dubuc A., Mack S., Shih D., Remke M., Al-Halabi H., Albrecht S., Jabado N., Eberhart C.G., Grajkowska W., Weiss W.A., Clifford S.C., Bouffet E., Rutka J.T., Korshunov A., Pfister S., Taylor M.D.: Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathol. 122 (2) 231-240, 2011.

Northcott P.A., Korshunov A., Witt H., Hielscher T., Eberhart C.G., Mack S., Bouffet E., Clifford S.C., Hawkins C.E., French P., Rutka J.T., Pfister S., Taylor M.D.: Medulloblastoma comprises four distinct molecular variants. J.Clin.Oncol. 29 (11) 1408-1414, 2011.

Olk-Batz C., Pötsch A., Nölke P., Claus R., Zucknick M., Sandrock I., Witte T., Strahm B., Hasle H., Zecca M., Stary J., Bergsträsser E., De Moerloose B., Trebo M., van den Heuvel-Eibrink M.M., Wojcik D., Locatelli F., Plass C., Niemeyer C.M., Flotho C.: Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. Blood 117 (18) 4871-4880, 2011.

Pfaff E., Remke M., Sturm D., Benner A., Witt H., Milde T., von Büren A.O., Jorch N., Graf N., Kulozik A., Witt O., Scheurlen W., von Deimling A., Rutkowski S., Taylor M.D., Tabori U., Lichter P., Korshunov A., Pfister S.M.: TP53 Mutations in favorable-risk WNT/wingless-subtype medulloblastomas reply (Letter). J.Clin.Oncol. 29 (12) E348-E349, 2011.

Qureshi N.R., Hintze C., Risse F., Kopp-Schneider A., Eberhardt R., Kauczor H.U., Delorme S.: The feasibility of low mechanical index contrast enhanced ultrasound (CEUS) in distinguishing malignant from benign thoracic lesions. Ultrasound Med.Biol. 37 (11) 1747-1754, 2011.

Reissfelder C., Timke C., Schmitz-Winnenthal H., Rahbari N.N., Koch M., Klug F., Röder F., Edler L., Debus J., Büchler M.W., Beckhove P., Huber P.E., Weitz J.: A randomized controlled trial to investigate the influence of low dose radiotherapy on immune stimulatory effects in liver metastases of colorectal cancer. BMC Cancer 11 419, 2011.

Remke M., Hielscher T., Korshunov A., Northcott P.A., Bender S., Kool M., Westermann F., Benner A., Cin H., Sturm D., Witt H., Haag D., Toedt G., von Büren A.O., Rutkowski S., Scheurlen W., Kulozik A.E., Taylor M.D., Lichter P., Pfister S.M.: FSTL5 Expression constitutes a marker of poor prognosis in non-WNT/SHH medulloblastoma. Neuro-Oncol. 13(Suppl.1), p.I13-I14, 2011.

Remke M., Hielscher T., Korshunov A., Northcott P.A., Bender S., Kool M., Westermann F., Benner A., Cin H., Ryzhova M., Sturm D., Witt H., Haag D., Tödt G., Wittmann A., Schöttler A., Büren A.O.v., Deimling A.v., Rutkowski S., Scheurlen W., Kulozik A.E.: FSTL5 is a marker of poor prognosis in non-WNT/ non-SHH medulloblastoma. J.Clin.Oncol. 29 (29) 3852-3861, 2011.

Remke M., Hielscher T., Northcott P.A., Witt H., Ryzhova M., Wittmann A., Benner A., von Deimling A., Scheurlen W., Perry A., Croul S., Kulozik A.E., Lichter P., Taylor M.D., Pfister S.M., Korshunov A.: Adult medulloblastoma comprises three major molecular variants. J.Clin.Oncol. 29 (19) 2717-2723, 2011.

Schäfer W.R., Fischer L., Roth K., Jüllig A.K., Stuckenschneider J.E., Schwartz P., Weimer M., Orlowska-Volk M., Hanjalic-Beck A., Kranz I., Deppert W.R., Zahradnik H.P.: Critical evaluation of human endometrial explants as an ex vivo model system: a molecular approach. Mol.Hum.Reproduct. 17 (4) 255-265, 2011.

Schlampp I., Karger C.P., Jäkel O., Scholz M., Didinger B., Nikoghosyan A., Hoess A., Krämer M., Edler L., Debus J., Schulz-Ertner D.: Temporal lobe reactions after radiotherapy with carbon ions: incidence and estimation of the relative biological effectiveness by the local effect model. Int.J.Radiat.Oncol.Biol.Phys. 80 (3) 815-823, 2011.

Schmid M., Hielscher T., Augustin T., Gefeller O.: A robust alternative to the Schemper-Henderson estimator of prediction error. Biometrics 67, 524-535, 2011.

Sill M., Kaiser S., Benner A., Kopp-Schneider A.: Robust biclustering by sparse singular value decomposition incorporating stability selection. Bioinformat. 27 (15) 2089-2097, 2011.

Tödt G., Barbus S., Wolter M., Felsberg J., Tews B., Blond F., Sabel M.C., Hofmann S., Becker N., Hartmann C., Ohgaki H., von Deimling A., Wiestler O.D., Hahn M., Lichter P., Reifenberger G., Radlwimmer B.: Molecular signatures classify astrocytic gliomas by IDH1 mutation status. Int.J.Cancer 128 (5) 1095-1103, 2011.

Viarisio D., Müller-Decker K., Kloz U., Aengeneyndt B., Kopp-Schneider A., Gröne H.J., Gheit T., Flechtenmacher C., Gissmann L., Tommasino M.: E6 and e7 from Beta hpv38 cooperate with ultraviolet light in the development of actinic keratosis-like lesions and squamous cell carcinoma in mice. PLoS_PATHOG. 7 (7) e1002125, 2011.

Vöglein J., Tüttenberg J., Weimer M., Gerigk L., Kauczor H.U., Essig M., Weber M.A.: Treatment monitoring in gliomas comparison of dynamic susceptibility-weighted contrast-enhanced and spectroscopic MRI techniques for identifying treatment failure. Invest.Radiol. 46 (6) 390-400, 2011.

Weber T.F., Tengg-Kobligk H.v., Kopp-Schneider A., Ley-Zaporozhan J., Kauczor H.U., Ley S.: High-resolution phase-contrast MRI of aortic and pulmonary blood flow during rest and physical exercise using a MRI compatible bicycle ergometer. Eur.J.Radiol. 80 (1) 103-108, 2011.

Witt H., Mack S.C., Ryzhova M., Bender S., Sill M., Isserlin R., Benner A., Hielscher T., Milde T., Remke M., Jones D.T., Northcott P.A., Garzia L., Bertrand K.C., Wittmann A., Yao Y., Roberts S.S., Massimi L., Van Meter T., Weiss W.A., Gupta N., Grajkowska W., Lach B., Cho Y.J., Deimling A.v., Kulozik A.E., Witt O., Bader G.D., Hawkins C.E., Tabori U., Guha A., Rutka J.T., Lichter P., Korshunov A., Taylor M.D., Pfister S.M.: Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 20 (2) 143-157, 2011.